Home/Pipeline/MUC1*-Targeted ADC

MUC1*-Targeted ADC

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Minerva Biotechnologies

About Minerva Biotechnologies

Minerva Biotechnologies is a clinical-stage biotech targeting a foundational oncology target, MUC1*, present on approximately 80% of solid tumors. Its lead programs include MUC1*-targeted CAR T-cell therapies and antibody-drug conjugates (ADCs) for cancers like breast, lung, ovarian, and pancreatic. In parallel, the company has leveraged its discoveries in stem cell biology to develop the AlphaSTEM® platform, aimed at improving the generation and differentiation of induced pluripotent stem cells (iPSCs) for regenerative medicine applications.

View full company profile

Therapeutic Areas

Oncology Regenerative Medicine

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed